Acquired Paludrine-Resistance in Plasmodium Gallinaceum

REFERENCES

• Acheson, R. M., King, F. E., and Spensley, P. C. (1947). Benziminazoles related to paludrine. [Correspondence.] Nature, Lond., 160, 53.
   Web of Science ®Google Scholar
• Adams, A. R. D., and Sanderson, G. (1945). Studies on synthetic antimalarial drugs. III: A preliminary investigation of the therapeutic action of 3349 on acute attacks of benign tertian malaria. Ann. Trop. Med. Parasit., 39, 165.
   PubMed Web of Science ®Google Scholar
• Bishop, Ann, and Birkett, Betty (1947). Acquired resistance to paludrine in Plasmodium gallinaceum: acquired resistance and persistence after passage through the mosquito. Nature, Lond., 159, 884.
   PubMed Web of Science ®Google Scholar
• Coatney, G. R., and Cooper, W. C. (1944). The prophylactic effect of sulfadiazine and sulfaguanidine against mosquito-borne Plasmodium gallinaceum infection in the domestic fowl (preliminary report). Publ. Hlth Rep., Wash., 59, 1455.
   PubMedGoogle Scholar
• Coggeshall, L. T., Porter, R. J., and Laird, R. L. (1944). Prophylactic and curative effects of certain sulfonamide compounds on exoerythrocytic stages in Plasmodium gallinaceum malaria. Proc. Soc. Exp. Biol., N.Y., 57, 286.
   Google Scholar
• Curd, F. H. S., Davey, D. G., and Rose, F. L. (1945A). Studies on synthetic antimalarial drugs. II: General chemical considerations. Ann. Trop. Med. Parasit., 39, 157.
   PubMed Web of Science ®Google Scholar
• Curd, F. H. S., Davey, D. G., and Rose, F. L. (1945B). Studies on synthetic antimalarial drugs. X: Some biguanide derivatives as new types of antimalarial substances with both therapeutic and causal prophylactic activity. Ibid., 39, 208.
   Google Scholar
• Curd, F. H. S., Davey, D. G. and Rose, F. L. (1946). A possible mode of action of ‘Paludrine.’ [Correspondence.] Nature, Lond., 158, 707.
   PubMed Web of Science ®Google Scholar
• Davey, D. G. (1946a). The use of avian malaria for the discovery of drugs effective in the treatment and prevention of human malaria. I: Drugs for clinical treatment and clinical prophylaxis. Ann. Trop. Med. Parasit., 40, 52.
   PubMed Web of Science ®Google Scholar
• Davey, D. G. (1946B). The use of avian malaria for the discovery of drugs effective in the treatment and prevention of human malaria. II: Drugs for causal prophylaxis and radical cure or the chemotherapy of exoerythrocytic forms. Ibid., 40, 453.
   Google Scholar
• Eagle, H. (1945). A new trypanocidal agent: γ-(p-arsenosophenyl)-butyric acid. Science, 101, 69.
   PubMed Web of Science ®Google Scholar
• Ehrlich, P. (1909). Über die neuesten Ergebnisse auf dem Gebiete der Trypanosomenforschung. Arch. Schiffs- u. Tropenhyg., 13, Bhft., 321.
   Google Scholar
• Fairley, N. H., et al. (1946). Researches on Paludrine (M.4888) in malaria: an experimental investigation undertaken by the L.H.Q. Medical Research Unit (A.I.F.), Cairns, Australia. Trans. R. Soc. Trop. Med. Hyg., 40, 105.
   PubMed Web of Science ®Google Scholar
• Fulton, J. D. (1942). Attempts to prepare in fowls a strain of Plasmodium gallinaceum resistant to plasma-quine. Ann. Trop. Med. Parasit., 36, 75.
   Google Scholar
• Fulton, J. D. and Yorke, W. (1941). Studies in chemotherapy. XXIX: The development of plasmoquine-resistance in Plasmodium knowlesi. Ibid., 35, 233.
   Google Scholar
• Fulton, J. D. and Yorke, W. (1943). Studies in chemotherapy. XXXII: Further observations on plasmoquine-resistance in Plasmodium knowlesi. Ibid., 37, 41.
   Google Scholar
• James, S. P., and Tate, P. (1937). New knowledge of the life-cycle of malaria parasites. [Correspondence.] Nature, Lond., 139, 545.
   Google Scholar
• Kikuth, W., and Mudrow, Lilly (1939). Chemotherapeutische Untersuchtingen an den endothelialen Formen (E.-Stadien) des Plasmodium cathemerium. Z. Immun Forsch., 95, 285.
   Google Scholar
• King, H. (1943). Chemical structure of arsenicals and drug-resistance of trypanosomes. Trans. Faraday Soc., 39, 383.
   Google Scholar
• King, H. and Strangeways, Winifred I. (1942). Some observations on the relation between chemical structure and drug-resistance among arsenicals. Ann. Trop. Med. Parasit., 36, 47.
   Google Scholar
• Lourie, E. M. (1934). Studies on chemotherapy in bird malaria. III: Difference in response to quinine treatment between strains of Plasmodium relictum of widely separated geographical origins. Ibid., 28, 513.
   Google Scholar
• Lourie, E. M. (1935). Studies on chemotherapy in bird malaria. IV: Failure to promote drug-resistance in Plasmodium cathemerium by prolonged administration of quinine or plasmochin. Ibid., 29, 421.
   Google Scholar
• McCance, R. A., and Widdowson, E. M. (1946). Observations on the administration of BAL-Intrav to man. [Correspondence.] Nature, Lond., 157, 837.
   PubMed Web of Science ®Google Scholar
• Maegraith, B. G., Adams, A. R. D., King, J. D., Tottey, Mary M., Rigby, D. J., and Sladden, R. A. (1946). Paludrine in the treatment of malaria. Brit. Med. J., 1, 903.
   Web of Science ®Google Scholar
• Marshall, E. K., Litchfield, J. T., and White, H. J. (1942). Sulfonamide therapy of malaria in ducks. J. Pharmacol., 75, 89.
   Google Scholar
• Peters, R. A., Stocken, L. A., and Thompson, R. H. S. (1945). British anti-lewisite (BAL). Nature, Lond., 156, 616.
   PubMed Web of Science ®Google Scholar
• Van Hoof, L. (1947). Observations on trypanosomiasis in the Belgian Congo. Trans. R. Soc. Trop. Med. Hyg., 40, 728.
   PubMed Web of Science ®Google Scholar
• Williamson, J., Bertram, D. S., and Lourie, E. M. (1947). Acquired resistance to paludrine in Plasmodium gallinaceum: effects of paludrine and other antimalarials. Nature, Lond., 159, 885.
   PubMed Web of Science ®Google Scholar
• Williamson, J., Bertram, D. S. and Lourie, E. M. (1946). Interference with the trypanocidal action of γ-(p-arsenosophenyl)butyric acid by p-aminobenzoic acid. Ann. Trop. Med. Parasit., 40, 255.
   PubMed Web of Science ®Google Scholar
• Yorke, W., Murgatroyd, F., and Hawking, F. (1932). Studies in chemotherapy. VIII: Comparison of strains of T. rhodesiense made resistant to various arsenicals and antimonials, to Bayer 205, and to acriflavine, respectively. Ibid., 26, 577.
   Google Scholar